Credit Suisse Group Analysts Give Sarepta Therapeutics (SRPT) a $81.00 Price Target
Credit Suisse Group set a $81.00 target price on Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other brokerages have also recently weighed in on SRPT. HC Wainwright started coverage on Sarepta Therapeutics in a research note on Friday, December 1st. They set a buy rating and a $75.00 price objective on the stock. Zacks Investment Research cut Sarepta Therapeutics from a buy rating to a hold rating in a research note on Friday, December 15th. BidaskClub cut Sarepta Therapeutics from a buy rating to a hold rating in a research note on Tuesday, December 19th. UBS Group reissued an outperform rating and set a $56.51 price objective (down from $76.00) on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Finally, Oppenheimer reissued a buy rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $67.59.
Shares of Sarepta Therapeutics (SRPT) traded up $5.85 during mid-day trading on Friday, hitting $67.96. The stock had a trading volume of 3,241,734 shares, compared to its average volume of 1,440,000. Sarepta Therapeutics has a 1 year low of $28.14 and a 1 year high of $68.90. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $4,810.00, a PE ratio of -84.95 and a beta of 1.51.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hall Laurie J Trustee boosted its holdings in shares of Sarepta Therapeutics by 2,430.8% in the fourth quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 3,160 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Sarepta Therapeutics by 39.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 977 shares during the period. Prentiss Smith & Co. Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $199,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $217,000. Finally, Aperio Group LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $219,000. 86.62% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/03/credit-suisse-group-analysts-give-sarepta-therapeutics-srpt-a-81-00-price-target.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.